Luye Pharma Ltd, a subsidiary of Luye Pharma Group has launched an innovative new product for the treatment of Alzheimer's disease.
Zeyzelf® twice weekly rivastigmine transdermal patch is for the symptomatic treatment of mild to moderately severe Alzheimer's dementia. It is the first ever product that Luye Pharma Group has launched from the beginning in the UK and the first rivastigmine patch that does not need to be applied daily.
There are currently 900,000 people with dementia in the UK, which is projected to rise to 1million by 2025 and nearly 1.6 million in 2040. Alzheimer's disease, which affects multiple brain functions, is the most common form of dementia and it is a progressive condition, with symptoms developing gradually over many years and eventually becoming more severe.
Zeyzelf® twice weekly is comparable to daily rivastigmine patches, but can be easier to administer and help the patient and caregiver maintain compliance.
The launch of Zeyzelf® twice weekly is part of Luye Pharma Ltd's focus on specialising in treatments for diseases of the central nervous system (CNS) and its overall vision of offering the UK National Health Service (NHS) cost effective and innovative medicines. The company believes Zeyzelf® twice weekly will offer a significant development in the treatment of Alzheimer's, as it is the first new product to come to the UK market in the last 10 years.
Said Andy Farrant, General Manager of Luye Pharma Ltd: “We are incredibly excited about the launch of Zeyzelf® twice weekly, as it marks a new treatment option for Alzheimer's dementia, a disease which is set to affect 1 million people in the next two years. There have been very few advancements in Alzheimer's in the past decade, so being at the forefront of a new treatment is something we are rightly proud of. The product has been incredibly well received in Spain where it launched last year and we look forward to it being widely used in the UK. Zeyzelf® twice weekly is now our third UK drug and we will be bringing more innovative products to market in 2024.”
Since Luye Pharma Ltd was established in the UK in 2019, the company has taken over distribution of Seroquel XL® and Seroquel® (quetiapine), for the treatment of schizophrenia and bipolar disorder, from Astra Zeneca and reversed its decline in UK sales. Luye Pharma Ltd has also repatriated and re-launched Fencino® (transdermal fentanyl patches) for the management of severe chronic pain. Fencino® is manufactured in the Group's manufacturing facility in Miesbach, Germany, and is distributed directly to the UK NHS.
Luye Pharma Ltd also plans to launch next year a Transdermal Rotigotine patch for Parkinson's disease, which will also be manufactured in Miesbach. In addition, the company will add to its drug portfolio a novel extended release version of gabapentin, in-licensed from another pharmaceutical manufacturer to treat neuropathic pain (post herpetic neuralgia).